DarioHealth Corp. splits its revenue into 12 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Services at $14.9 million, 67% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21
|
22
|
27
|
20
|
28
|
21
|
8
|
8
|
7
|
5
|
3
|
| Product |
—
|
—
|
—
|
—
|
—
|
18
+208.5%
share 86.7%
|
6
share 76.1%
|
—
|
—
|
—
|
—
|
| Services |
12
-40.7%
share 56.2%
|
15
-26.1%
share 66.8%
|
20
share 74.7%
|
—
|
18
+556.6%
share 64.6%
|
3
+50.4%
share 13.3%
|
2
share 23.9%
|
—
|
—
|
—
|
—
|
| Sales Channel Strategic Partnerships |
—
|
—
|
—
|
—
|
13
share 46.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Consumers |
—
|
—
|
—
|
8
share 40.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Hardware And Consumable Products |
9
+27.1%
share 43.8%
|
7
+8.6%
share 33.2%
|
7
-5.8%
share 25.3%
|
7
-25.8%
share 35.7%
|
10
share 35.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Development Services Per Exclusive Agreement |
—
|
—
|
—
|
—
|
6
share 19.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Sales Channel Business To Business To Consumer B2b2c |
—
|
—
|
—
|
5
+39.3%
share 24.6%
|
4
share 13.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Development Services Per Exclusive Agreement Year One |
—
|
—
|
—
|
—
|
4
share 14.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Development Services Per Exclusive Agreement Year Two |
—
|
—
|
—
|
2
share 12.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Development Services Per Exclusive Agreement Year Three |
—
|
—
|
—
|
2
share 10.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| National Health Plan Statement Of Work Agreement |
—
|
—
|
—
|
1
-45.9%
share 4.7%
|
2
share 6.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Saas Services |
—
|
—
|
0
share 1.1%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- DRIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1533998
- Former names
- LabStyle Innovations Corp. (until Jul 27, 2016)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.